Literature DB >> 23871511

Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice.

Nicolas M Van Mieghem1, Robert M van der Boon, Elhamula Faqiri, Roberto Diletti, Carl Schultz, Robert-Jan van Geuns, Patrick W Serruys, Arie-Pieter Kappetein, Ron T van Domburg, Peter P de Jaegere.   

Abstract

OBJECTIVES: This study sought to assess in patients undergoing transcatheter aortic valve implantation (TAVI), the prevalence and impact of incomplete coronary revascularization defined as >50% coronary artery or graft diameter stenosis on visual assessment of the coronary angiogram.
BACKGROUND: TAVI is an established treatment option in elderly patients with aortic stenosis (AS) and a (very) high operative risk. Coronary artery disease (CAD) is often associated with AS.
METHODS: A single-center cohort of consecutive patients undergoing TAVI between November 2005 and June 2012 was evaluated for the presence of significant CAD. The decision to revascularize and pursue complete revascularization was made by heart team consensus.
RESULTS: A total of 263 consecutive patients with a mean age of 80 ± 7 years and 51% male underwent TAVI with a median follow-up duration of 16 months (interquartile range: 4.2 to 28.1 months). Significant CAD with myocardium at risk was present in 124 patients (47%), 44 of whom had had previous coronary artery bypass grafting (CABG), and the median SYNTAX score in the 81 patients without previous CABG was 9.00 (2.38 to 15.63). Staged percutaneous coronary intervention (PCI) was planned in 19 (15%) and concomitant PCI with TAVI in 20 (16%). The median post-procedural residual SYNTAX score of patients without prior CABG was 5.00 (0.13 to 9.88). Overall, 99 patients (37%) (61 with no CABG and 38 CABG patients) had incomplete revascularization after TAVI. Revascularization status did not affect clinical endpoints. Kaplan-Meier survival curves for patients with and without complete revascularization demonstrated a 1-year mortality of 79.9% versus 77.4% (p = 0.85), respectively.
CONCLUSIONS: In an elderly patient population undergoing TAVI for severe AS, a judicious revascularization strategy selection by a dedicated heart team can generate favorable mid-term outcome obviating the need for complete coronary revascularization.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACS; AS; CABG; CAD; IQR; PCI; SAVR; SYNTAX score; TAVI; acute coronary syndrome; aortic valve stenosis; coronary artery bypass grafting; coronary artery disease; interquartile range; percutaneous coronary intervention; revascularization; surgical aortic valve replacement; transcatheter aortic valve implantation

Mesh:

Year:  2013        PMID: 23871511     DOI: 10.1016/j.jcin.2013.04.015

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  20 in total

Review 1.  Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When?

Authors:  Davide Cao; Mauro Chiarito; Paolo Pagnotta; Bernhard Reimers; Giulio G Stefanini
Journal:  Interv Cardiol       Date:  2018-05

Review 2.  Timing and Outcomes of PCI in the TAVR Era.

Authors:  Konstantinos V Voudris; Peter Petropulos; Panagiotis Karyofillis; Konstantinos Charitakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

3.  Revascularizing coronary artery disease in patients undergoing transcatheter aortic valve implantation.

Authors:  Rafail A Kotronias; Mamas A Mamas; Rodrigo Bagur
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 4.  Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management.

Authors:  Matthew W Sherwood; Amit N Vora
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

5.  Management of Coronary Artery Disease and Conduction Abnormalities in Transcatheter Aortic Valve Implantation.

Authors:  Anna Kostopoulou; Panagiotis Karyofillis; Efthimios Livanis; George Karavolias; George Theodorakis; John Paraskevaides; Vassilis Voudris
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

Review 6.  Assessment, treatment, and prognostic implications of CAD in patients undergoing TAVI.

Authors:  Edward Danson; Peter Hansen; Sayan Sen; Justin Davies; Ian Meredith; Ravinay Bhindi
Journal:  Nat Rev Cardiol       Date:  2016-02-11       Impact factor: 32.419

7.  Routine CT angiography to detect severe coronary artery disease prior to transcatheter aortic valve replacement.

Authors:  S Chava; G Gentchos; A Abernethy; B Leavitt; E Terrien; H L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

8.  Clinical Outcome of Patients with Aortic Stenosis and Coronary Artery Disease Not Treated According to Current Recommendations.

Authors:  Giuseppe Di Gioia; Mariano Pellicano; Gabor G Toth; Filip Casselman; Julien Adjedj; Frank Van Praet; Bernard Stockman; Ivan Degrieck; Bruno Trimarco; William Wijns; Bernard De Bruyne; Emanuele Barbato
Journal:  J Cardiovasc Transl Res       Date:  2016-02-16       Impact factor: 4.132

Review 9.  Myocardial injury associated with transcatheter aortic valve implantation (TAVI).

Authors:  Won-Keun Kim; Christoph Liebetrau; Arnaud van Linden; Johannes Blumenstein; Luise Gaede; Christian W Hamm; Thomas Walther; Helge Möllmann
Journal:  Clin Res Cardiol       Date:  2015-12-15       Impact factor: 5.460

10.  Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation.

Authors:  Jennifer Mancio; Ricardo Fontes-Carvalho; Marco Oliveira; Daniel Caeiro; Pedro Braga; Nuno Bettencourt; Vasco Gama Ribeiro
Journal:  Front Cardiovasc Med       Date:  2015-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.